Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Palantir Technologies is targeting a valuation of at least $26 billion in a private fundraising round, the first for the Peter Thiel-backed data analytics startup in four...Wall Streetread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The New England Patriots released Antonio Brown just 11 days after signing the wide receiver. The NFL Super Bowl champions initially had kept him in the face of a rape claim,...Sportsread more
The Wall Street Journal's report came as a top Ukraine official said President Donald Trump "is looking" for Ukraine officials to investigate business dealings of Biden's son...Politicsread more
A tour bus carrying Chinese-speaking tourists crashed near a national park in southern Utah, killing at least four people and critically injuring up to 15 others, authorities...U.S. Newsread more
Gun maker Colt announced Thursday that it will halt its production of AR-15 rifles for civilian sales, but the news might not be as exciting for gun control advocates as it...Guns and Weaponsread more
As thousands of people across the world participate in the Global Climate Strike, several Democratic presidential candidates have shared how they will take aggressive action...Scienceread more
The price war over new hepatitis C drugs just heated up.
The nation's largest pharmacy benefits manager, Express Scripts, said its largest plan will cover only AbbVie's newly approved hepatitis C regimen for patients with the most common form of the virus. Starting Jan. 1, it will exclude drugs from Gilead Sciences and Johnson & Johnson for that indication.
AbbVie's Viekira Pak was approved Friday, and the company said it will have a price of $83,319. In an interview on CNBC's "Squawk Box," Express Scripts Chief Medical Officer Steve Miller declined to disclose the terms of the deal but said Abbvie's discount was big enough to allow Express Scripts to recommend treating all patients with genotype 1 hepatitis C.
"We think when we find partners like this. We can really move drug prices and get more patients treated and more patients cured," he said.
Asked whether Express Scripts would form similar deals in other therapeutic areas including diabetes and cancer where there are high drug costs and multiple drugs on the market, Miller said he saw opportunities in those categories. He added that companies must do something because drug prices have become unsustainable.
Gilead's Sovaldi sparked a fierce debate over the cost of drugs after it was approved in December 2013 and its price set at $84,000 for 12 weeks of treatment, or about $1,000 a day. The drug, along with Johnson & Johnson's Olysio and Gilead's combination medicine, Harvoni, represent a significant improvement over previous therapies, which didn't cure all patients, were given by injection and came with side effects that could make them difficult to take.
The ease of use and higher cure rates drove swift uptake of the drugs; Sovaldi brought in $8.6 billion in revenue in the first three quarters of 2014. Harvoni, a combination of Sovaldi and another drug, costs $94,500 for 12 weeks, or about $63,000 for patients who only require eight weeks of treatment. Analysts estimate the drug may draw $2.8 billion to $3 billion in fourth quarter revenue for Gilead, after approval on Oct. 10.
AbbVie's regimen includes several pills a day, taken at different times, while Gilead's Harvoni is one pill taken once a day. Some patients on AbbVie's therapy may also require ribavirin, another drug that can carry unpleasant side effects.
Express Scripts said its independent Pharmacy & Therapeutics Committee determined AbbVie's Viekira Pak to be "at least clinically equivalent" to Harvoni and Sovaldi, and that it would make the therapy the exclusive option for genotype 1 patients with hepatitis C on its National Preferred Formulary, which covers about 25 million Americans.
Sovaldi and Harvoni, as well as J&J's Olysio, will be excluded from the National Preferred Formulary, though patients who have already begun treatment before Jan. 1 will continue to receive coverage. Sovaldi will remain on the formulary for patients with other kinds of the virus who have advanced liver disease, Express Scripts said.
About 3.2 million people in the U.S. have hepatitis C, according to the Centers for Disease Control and Prevention. Three-quarters of those have genotype 1, Express Scripts said. The viral infection affects as many as 150 million people worldwide; it is spread through the blood and can lead to liver failure and liver cancer. As many as 500,000 people worldwide die of hepatitis C-related liver diseases each year, according to the World Health Organization.